GlassScriptPhysician profile
Eugene L Young
NPI 1720062318
$6,760.17
in general payments reported to CMS, 2019-2025
26 companies · $1,148 in 2025
The $1,148 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $893 · 2020: $548 · 2021: $704 · 2022: $881 · 2023: $1,577 · 2024: $1,009 · 2025: $1,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,673 · Education: $60.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,673.14 |
| Education | $60.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,153.43 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $933.59 | 2019-2024 | Xifaxan, Trulance |
| Pfizer INC. | $692.62 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $527.23 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $508.15 | 2019-2025 | Stelara, Tremfya, Simponi |
| Genzyme Corporation | $477.91 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $152.24 | 2022-2023 | Zeposia |
| Boston Scientific Corporation | $148.91 | 2025 | Watchman Flx |
| Nestle Healthcare Nutrition INC. | $145.71 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $137.21 | 2019-2022 | |
| Evoke Pharma, INC. | $135.50 | 2020-2024 | Gimoti |
| Qol Medical, LLC | $121.22 | 2019-2025 | Sucraid |
| Phathom Pharmaceuticals, INC. | $118.24 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $89.37 | 2020-2023 | Dificid |
| Madrigal Pharmaceuticals | $63.62 | 2025 | Rezdiffra |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $58.53 | 2023-2024 | Dupixent |
| Braintree Laboratories, INC. | $54.70 | 2020-2022 | |
| Cook Medical LLC | $47.02 | 2019 | |
| Daiichi Sankyo INC. | $43.81 | 2019-2020 | |
| Celltrion USA INC. | $42.48 | 2025 | Vegzelma |
| Celgene Corporation | $24.81 | 2022 | |
| Redhill Biopharma INC. | $20.32 | 2023 | Movantik, Talicia, Aemcolo |
| Amgen INC. | $18.68 | 2023 | Amjevita |
| Aimmune Therapeutics, INC. | $16.14 | 2024 | |
| Intercept Pharmaceuticals, INC. | $15.02 | 2023 | Ocaliva |
| Ardelyx, INC. | $13.71 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.